ライフサイエンスコーパス: infectious virion

1 d to ensure that the resulting complex is an infectious virion.

2 o copies of the RNA genome as a dimer in the infectious virion.

3 28 multimerization in the envelopment of the infectious virion.

4 ht segments of viral RNA (vRNA) into a fully infectious virion.

5 nts that must each be packaged to produce an infectious virion.

6 maturation, and convert the particle into an infectious virion.

7 ll membrane and bud to form an immature, non-infectious virion.

8 nce there may be no single structure for the infectious virion.

9 all of which must be packaged to produce an infectious virion.

10 of the immature virus-like particle into an infectious virion.

11 the maturation pathway that give rise to an infectious virion.

12 l core particle located at the center of the infectious virion.

13 en packaging this recombinant genome into an infectious virion.

14 lar conformation of the DNA genome within an infectious virion.

15 capsid are essential for the assembly of an infectious virion.

16 Gp16 then fastens the tail to yield the infectious virion.

17 mmature VP70 virion and a fully proteolyzed, infectious virion.

18 ortal but lacking DNA, which matures into an infectious virion.

19 ells were able to produce only low levels of infectious virions.

20 g antibody 2G12 MAb that bound predominantly infectious virions.

21 bly and ultimately budding and maturation of infectious virions.

22 iruses and bacteriophages, is key to forming infectious virions.

23 y strong ability of this antibody to capture infectious virions.

24 ellular components come together to generate infectious virions.

25 M2 protein is required for the production of infectious virions.

26 cell-cell fusion, bypassing the need to bud infectious virions.

27 e right place and time to ensure assembly of infectious virions.

28 ginning 24 h postinfection failed to produce infectious virions.

29 all of which are required for generation of infectious virions.

30 t are morphologically indistinguishable from infectious virions.

31 and in genomic RNA dimer structures to yield infectious virions.

32 plasm is a prerequisite for the formation of infectious virions.

33 s) and producing relatively large numbers of infectious virions.

34 nfection and produced substantial numbers of infectious virions.

35 al step in the envelopment and production of infectious virions.

36 is required for the efficient production of infectious virions.

37 de motifs in Gag that promote the release of infectious virions.

38 differentiation of the host cell to produce infectious virions.

39 tic machinery, which results in formation of infectious virions.

40 ) completely inhibited further production of infectious virions.

41 for genome replication or for production of infectious virions.

42 limited by the insufficient availability of infectious virions.

43 t H84 produced assembly-competent but poorly infectious virions.

44 for virus replication and the maturation of infectious virions.

45 aged with other serotype capsids to assemble infectious virions.

46 of infection to facilitate the production of infectious virions.

47 orated into the AAV genome and packaged into infectious virions.

48 oblasts but did not rescue the production of infectious virions.

49 to either AAV-2 or AAV-5 capsids to generate infectious virions.

50 s a maturation step during assembly to yield infectious virions.

51 ease that is essential for the maturation of infectious virions.

52 esulting in the severe loss of production of infectious virions.

53 t HCV replication, but not the production of infectious virions.

54 that resemble the distinctively filamentous infectious virions.

55 preintegration complexes (PICs) derived from infectious virions.

56 cid code that dictates genome packaging into infectious virions.

57 quired for efficient budding and assembly of infectious virions.

58 seudotyped with the AAV-5 capsid to assemble infectious virions.

59 e proteins is required for the production of infectious virions.

60 stantial levels of HIV-1 p24 CA and produced infectious virions.

61 n plays a critical role in the production of infectious virions.

62 used to BPV1 L2 residues 99 to 469 generated infectious virions.

63 onal changes transform viral precursors into infectious virions.

64 ted by production of viral late proteins and infectious virions.

65 , but did not produce HSV-1 late proteins or infectious virions.

66 ation in yeast, culminating in production of infectious virions.

67 of envelope glycoprotein epitopes exposed on infectious virions.

68 m infection reflects increased production of infectious virions.

69 BPV) proteins in cultured cells that produce infectious virions.

70 subunit interactions and formed VLPs but not infectious virions.

71 ag/Pol are not required for the formation of infectious virions.

72 All three clones produced infectious virions.

73 cells infected by Av3nBg did not accumulate infectious virions.

74 replication, transcription, and assembly of infectious virions.

75 ture noninfectious viral particles to mature infectious virions.

76 is required for the efficient production of infectious virions.

77 the virus to express viral genes and produce infectious virions.

78 ges undergo productive infection and release infectious virions.

79 produced by SFTS virus-infected cells harbor infectious virions.

80 h active virus replication and production of infectious virions.

81 ociation with a 2-log drop in the release of infectious virions.

82 anscripts and proteins and the production of infectious virions.

83 ependent cleavage event in the generation of infectious virions.

84 n of Gag and Env for efficient production of infectious virions.

85 ral proteins and as the genome packaged into infectious virions.

86 lasmic envelopment and overall production of infectious virions.

87 genes that participate in the generation of infectious virions.

88 together have improved capacity to recognize infectious virions.

89 suggesting that the fusion loop is hidden in infectious virions.

90 earrangement of the particles to form mature infectious virions.

91 c gene ORF65 and increased the production of infectious virions.

92 solution 3D structural information of highly infectious virions.

93 or the impact they have on the production of infectious virions.

94 V) 5'UTR, leading to increased production of infectious virions.

95 nd gp120 conformational) mediated capture of infectious virions.

96 the capsid that function in the assembly of infectious virions.

97 state but produces neither conical cores nor infectious virions.

98 f a PFV Gag-Pol protein with Gag can produce infectious virions.

99 e filaments, which are believed to represent infectious virions.

100 her viral DNA synthesis or the production of infectious virions.

101 eins upon DNA packaging, and maturation into infectious virions.

102 Mutant delta gK and F-gKbeta infectious virions accumulated within Vero and HEp-2 cel

103 ere found to be permissive for production of infectious virions after circumventing the cellular entr

104 t to hygromycin, expressed GFP, and produced infectious virions after induction with tetradecanoyl ph

105 The gH/UL116 complex is carried on the infectious virions, although in smaller amounts than gH/

106 in sensory neurons without the production of infectious virions and "reactivation" as a multistep pro

107 nduced G9 protein was associated with mature infectious virions and could be labeled with a membrane-

108 udorevertants of mutant 5B-741 that released infectious virions and formed plaques revealed a single

109 human eosinophils results in the release of infectious virions and in the release of the proinflamma

110 efects in cVAC development and production of infectious virions and produce small plaques and intrace

111 replicated as extensively as rOka, producing infectious virions and significant cytopathic effects wi

112 t results in the synthesis and maturation of infectious virions and that the ORF3 nucleotide sequence

113 icicol potently suppressed the production of infectious virions and the accumulation of protein A and

114 phils (bmEos) likewise results in release of infectious virions and the proinflammatory mediators IL-

115 major deleterious effects on the assembly of infectious virions and their subsequent ability to infec

116 ral proteins and RNA are encapsidated in the infectious virions and transduced into the infected cell

117 ts, termed virion RNAs, were packaged within infectious virions and were delivered to the host cell o

118 56 products were found to be associated with infectious virions, and antibodies to BVp56 had neutrali

119 ted U1 cells, DIBAs inhibited the release of infectious virions, and even under conditions in which v

120 ticles is an essential step in production of infectious virions, and requires proteolytic cleavage of

121 as a swarm of complementation-dependent semi-infectious virions, and thus traditional, propagation-de

122 VP22 packaged into infectious virions appears undermodified, and nuclear- a

123 , but also was capable of robustly producing infectious virions ( approximately 5 x 10(7)/ml).

124 tion, assembly, budding, and maturation into infectious virions are functional in restrictive cells.

125 vitro, X31-sciIV can infect MDCK cells, but infectious virions are not produced unless HA is transco

126 hly infectious human pathogen; nevertheless, infectious virions are not released in vitro where infec

127 n asymptomatic persistent infection in which infectious virions are shed in feces for several years.

128 ding shell, and C capsids-which develop into infectious virions-are filled with DNA and ostensibly ha

129 rus host shutoff) and incorporates them into infectious virions as efficiently as wild-type virus.

130 se is essential for the production of mature infectious virions, as it performs proteolytic processin

131 Gag interactions are the nucleation event of infectious virion assembly, ensuring that one RNA dimer

132 udies revealed an unexpected role of NS5B in infectious virion assembly.

133 productive replication of EIAV and produced infectious virions at levels similar to those found in a

134 palmitoylation-minus forms of GP64 produced infectious virions at levels similar to those from cells

135 izing antibodies inhibit virus by binding to infectious virions at the exposed MARV receptor-binding

136 CD8, can dramatically reduce the release of infectious virions bearing the HIV-1 envelope protein an

137 in human cells, thereby allowing release of infectious virions, but fails to inhibit similar APOBEC3

138 ome replication, and of de novo synthesis of infectious virions by a nonendogenous virus, in the yeas

139 ty factor) is required for the production of infectious virions by CD4(+) lymphocytes.

140 ole of cysteine residues in the formation of infectious virions by individually mutating the seven cy

141 protein that is necessary for production of infectious virions by nonpermissive cells (human lymphoc

142 -1 assembly leading to induced production of infectious virions by targeted modulation of Gag PM targ

143 Woot does not appear to generate infectious virions by the criterion that no envelop gene

144 Importantly, KV-1 was packaged as infectious virions by using regular KSHV as helpers, and

145 s form a differentiated epithelium such that infectious virions can be synthesized.

146 We determined the infectious virion capture index (IVCI) of different anti

147 Infectious virion capture was additive with a mixture of

148 ize for recognition of virus-infected cells, infectious virion capture, virus neutralization, and ant

149 at the exact conditions for determination of infectious virion concentration and bioactivity of recom

150 Remarkably, highly purified infectious virions contain almost exclusively viral RNA,

151 cted by the lack of methodologies to produce infectious virions containing engineered mutations in vi

152 ha backbone models for the P22 procapsid and infectious virion derived from electron cryomicroscopy d

153 duction resulted in low levels of detectable infectious virions despite robust expression of lytic ge

154 scovered that the form of VP22 packaged into infectious virions differed from VP22 extracted from inf

155 The ability to produce infectious virions does not require all six mutations.

156 hree MAPK pathways also reduced the yield of infectious virions during KSHV productive infection of H

157 ion kinetics identified disparate effects on infectious virion egress from infected cells.

158 Cells infected with one or more infectious virions excluded hundreds of superinfecting v

159 ergo maturational cleavage and go on to form infectious virions following downshift to permissive tem

160 ases, complete processing of NS2-3 prevented infectious virion formation without affecting RNA replic

161 on of other SM-dependent genes necessary for infectious virion formation.

162 in vivo and results in diminished release of infectious virions from alveolar macrophages.

163 eraction in vivo by measuring the release of infectious virions from E. coli F(+) cells infected with

164 he MA globular head can improve the yield of infectious virions from murine cells by >50-fold.

165 and more importantly in the translocation of infectious virions from the cytoplasm to the extracellul

166 The mature flavivirus infectious virion has 90 envelope (E) protein homo-dimer

167 ralization is unknown and no structure of an infectious virion has been reported.

168 The failure to assemble infectious virions has meant that the roles of these gen

169 uninfected donors were stimulated with HIV-1 infectious virions, HIV-1 ssRNA, TLR 7 and 8 agonists, o

170 n functions as a structural component of the infectious virion; however, it may have additional funct

171 To promote the release of infectious virions, human immunodeficiency virus type 1

172 The titers of infectious virions in both cell-free supernatants and ce

173 IE) gene transcription and the generation of infectious virions in cells in which HCMV latency is stu

174 sis, they significantly impaired assembly of infectious virions in infected cells.

175 replicate and produce high concentrations of infectious virions in permissive cells.

176 mmunodeficiency virus (SIV) RNA molecules to infectious virions in plasma, a ramp-up-stage plasma poo

177 type levels of viral structural proteins and infectious virions in the cell body.

178 and the role of Gag/Pol in the formation of infectious virions in the context of a replicating virus

179 nsiently expressing the K8.1A gene, produced infectious virions in the supernatants of transfected ce

180 In addition to carrying enveloped infectious virions in their lumen, HSV-bearing organelle

181 sue macrophages that can actively accumulate infectious virions in vacuolar subcellular structures mo

182 ed that B1 is critical for the production of infectious virions in various cell types and is sufficie

183 lacking assembly intermediates of phi29 into infectious virions in vitro.

184 cination elicited antibodies that could bind infectious virions (including the vaccine strains HIV-1

185 d of VV envelope proteins from both forms of infectious virions, including the extracellular envelope

186 from the surface, recovery of intracellular, infectious virions increased steadily up to 20 min posti

187 e the full-length papillomaviral genome into infectious virions, independently of viral DNA replicati

188 37 degrees C with mature virus, transforming infectious virions into A particles.

189 The infectious virion is an enveloped capsid containing the

190 The functional unit of Env on the surface of infectious virions is a trimer of gp120/gp41 heterodimer

191 of immature noninfectious HIV-1 particles to infectious virions is dependent upon the sequential clea

192 Of these, only the reduced production of infectious virions is not eliminated by chemically stabi

193 sembly of the viral structural proteins into infectious virions is often mediated by scaffolding prot

194 As a result, production of infectious virions is reduced in SCAP-depleted cells.

195 result of the nuclear retention, release of infectious virions is significantly retarded.

196 sitions from a noninfectious provirion to an infectious virion, is an ideal process to interrupt beca

197 supernatant from infected moDCs depleted of infectious virions, is nevertheless sufficient to cause

198 ate glycoproteins from other viruses to form infectious virions known as pseudotyped particles.

199 that complement pAD/CreDeltaUL55 and produce infectious virions lacking the UL55 gene but containing

200 52 is required for the optimal production of infectious virions, likely due to its roles in virion as

201 packaging of viral genomes and formation of infectious virions may involve factors other than CP and

202 importance of N-linked glycan processing in infectious virion morphogenesis.

203 mportance of these nonstructural proteins in infectious virion morphogenesis.

204 in a cooperative but not redundant manner in infectious virion morphogenesis.

205 Although mutations at H87 yielded infectious virions, mutations at H84 produced assembly-c

206 xcept for an MPER bNAb, selectively captured infectious virions, non-bNAbs and mucosal human immunode

207 tened permissiveness, the presence of highly infectious virions on follicular dendritic cells (FDCs),

208 zation of L2 and packaged DNA after entry of infectious virions or L1/L2 pseudovirions.

209 In the context of infectious virions, our results indicate a critical role

210 iplication correlated with delayed export of infectious virions out of infected cells but not with ch

211 was deficient in the assembly and release of infectious virion particles.

212 e virion assembly and the production of less infectious virion particles.

213 phage phi29 assembly system, in which 10(8) infectious virions per ml without background can be asse

214 this pocket, produced a large number of non-infectious virions, possibly because of modification in

215 s with alanines caused drastic inhibition of infectious virion production and cytoplasmic virion enve

216 confirmed that core protein is essential for infectious virion production and have identified numerou

217 f 45% mutant pRNA resulted in a reduction of infectious virion production by 4 orders of magnitude, i

218 in activity, apolipoprotein B secretion, and infectious virion production into culture supernatants.

219 Infectious virion production is activated by the essenti

220 mediated knockdown of DGAT1 severely impairs infectious virion production, implicating DGAT1 as a new

221 dramatically reduced DENV RNA synthesis and infectious virion production, revealing a requirement fo

222 permitted efficient HCV RNA replication and infectious virion production.

223 r trafficking, viral RNA nuclear export, and infectious virion production.

224 viral lytic cycle, contributing to efficient infectious virion production.

225 vRNP formation, viral lytic replication and infectious virion production.

226 NA replication, late protein expression, and infectious virion production.

227 MLV replication to direct virus release and infectious virion production.

228 EBV) DNA are numerically heterogeneous among infectious virions, providing a viral measure of clonali

229 fective in the surface display of HA and for infectious virion release.

230 ners present a risk for HCV transmission, as infectious virions remained associated with water contai

231 A key stage in HIV-1 maturation toward an infectious virion requires sequential proteolytic cleava

232 Very few infectious virions seem to be necessary to induce scid c

233 ids, a critical process in the production of infectious virions subsequent to DNA replication.

234 d structural proteins in a given quantity of infectious virions suggested that the ac79-knockout viru

235 esus CMV homolog RhUS28.5 to the envelope of infectious virions, suggesting a role in viral entry or

236 n of viral lytic genes and the production of infectious virions, suggesting the use of metformin as a

237 l maintenance, late promoter activation, and infectious virion synthesis, was examined.

238 ne of these essential processes, assembly of infectious virions, takes places in the cytoplasmic vira

239 ng all five mutations produced 3-4 logs more infectious virions than did wild type.

240 ein also significantly reduces the amount of infectious virions that are generated.

241 fection therefore depends on the fraction of infectious virions that are sufficiently saturated with

242 the epithelial or mucosal cells will produce infectious virions that can infect naive hosts.

243 es with envelopment in the cytoplasm to form infectious virions that egress the cell.

244 All three reconstructed proviruses produced infectious virions that replicated in human and chimpanz

245 s from cultures of DV-exposed MNCs contained infectious virions that were readily detectable by plaqu

246 unable to synthesize ORF3 protein contained infectious virions that were similar in number, thermost

247 ch, we demonstrated, for the first time with infectious virions, that the YMDD aspartates of p66 are

248 nlike the phiX174 "closed" procapsid and the infectious virion, the alpha3 open procapsid has 30A wid

249 ) minor structural protein VP2 is present in infectious virions, the available crystallographic and e

250 Vaccinia virus has two forms of infectious virions: the intracellular mature virus and t

251 e findings suggest that the cyanophages form infectious virions through the initial assembly of scaff

252 nd that the CTX(calc) prophage gives rise to infectious virions; thus, CTX(ET)phi is no longer the on

253 Furthermore, there is a high ratio of infectious virions to total virions in ramp-up-stage pla

254 e of viral glycoproteins on mature and fully infectious virions utilizing unique protease sites may s

255 While the reduction of infectious virions was in part due to the reduced infect

256 gen gene replication but avoid production of infectious virions, we developed "single-cycle" adenovir

257 lyze the role of Gag/Pol in the formation of infectious virions, we incorporated RT and IN into HIV-1

258 targets, the effects of envelope protein and infectious virions were directly compared.

259 Growth analyses showed that infectious virions were not produced in Vero or HEp-2 ce

260 regarded as sufficient for infectivity, yet infectious virions were not produced.

261 Infectious virions were recovered from rhesus fibroblast

262 Gag-Pol is not required for the formation of infectious virions when IN is provided in trans.

263 ZV, secreted lysosomal enzymes, and released infectious virions when infected by cell-associated VZV.

264 n of viral lytic genes and the production of infectious virions, while overexpression of a constituti

265 type (wt) HTLV-1, but rescued the release of infectious virions with certain mutations in the PPPY mo

266 ins of the DENV2 strain 16681, production of infectious virions with DENV2 strain New Guinea C (NGC)

267 RRV results in the release of high levels of infectious virions with genome-containing C capsids at t

268 4 results in severely impaired production of infectious virions, with a decrease as great as 5 logs.

269 The stable sequestration of infectious virions within cytoplasmic compartments of ma

270 f Shiga toxin-converting phages give rise to infectious virions within the host gastrointestinal trac

271 inding to viral RNA result in eccentric, non-infectious virions without affecting nucleocapsid-RNA in